Español English

Purpose Of A Transfer Agreement


The definition of materials should be limited to the definition of materials actually transferred, including unchanged descendants and derivatives, and should not include substances or inventions produced by the recipient of the materials. The descendants, as defined in the Uniform Biological Material Material Agreement (UBMTA), are unchanged descendants of the original material. Descendants may include a virus from a virus, a cell cell or an organism. The unchanged derivatives are, according to the UBMTA, substances produced by the recipient, which constitute an unchanged functional sub-unit or a product of expression of the material initially supplied. Unchanged derivatives may include purified or split subsets of the original material; descendants or derivatives; sub-clone of unchanged cell lines; transcription and translation products such as RNA and proteins from the DNA provided; Reverse translation and reverse translation products, such as DNA. B, are synthesized on a model with the RNA provided; monoclonal antibodies that are secreted by a line of hybrid cells; and chemically synthesized copies. Since a supplier generally asserts ownership of materials, the definition of materials should not exceed modifications, derivatives, cross-breeding (in animals), mutants or other substances that are not provided by the supplier. Raw material MTAs generally prevent the material supplier from losing control of the material and its use of research. In the absence of an agreement, the recipient of the material has no legal restrictions on the use of the equipment or the transfer of the material. The NIH believes that the exchange of research instruments is so important for the future advancement of research that the Agency has published strict guidelines for the transfer of research materials that contribute to or result from NIH-funded research.1 The NSF has also published guidelines for the release of data and materials and invites researchers to describe the timing of the , constraints and means to release developed material. , particularly for programs (such as the Plant Genome Research Program) that focus on the production of research resources and instruments.2 Since contractual agreements between two or more parties are ACCORDS, agreements generally do not have the geographical or temporal limits of patented technologies (patents are territorial, from countries with limited terms, usually 20 years after the filing date) and can therefore go well beyond the scope of patent rights. It is interesting to note that an assessment of property rights related to «GoldenRice» indicated that 44 patented products or processes and at least 15 materials, many of which were regulated by MTAs, were used in their development.5 When navigating the intellectual and technical real estate landscape around «GoldenRice,» Potrykus indicated that MTA restrictions were particularly problematic.6 That BIO members would enter into a «bioprospecting agreement» before including a physical bioprospecting agreement.

regulated genetic resources» in the field or when accessing these ex situ resources.